Melissa M. Taylor

Next Post

VectivBio Reports Full Year 2021 Financial Results and Provides Business Update

Thu Apr 14 , 2022
VectivBio AG Significant Progress Across Multiple Programs with Key Upcoming Catalysts Beginning H2 2022 STARS Phase 3 Program of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) On-Track for Topline Results at End of 2023 Cash Runway Extends Beyond Anticipated Release of Topline STARS Phase 3 Data Related Posts:The […]